We also determined that the strongest measure for predicting strength of HGF rescue in the BRAF mutant melanoma cell lines was the fold increase in MET levels following BRAF inhibitor treatment, suggesting that the induction of total MET may serve as a predictive biomarker to ascertain which patients with BRAFV600E mutant melanoma are most likely to exhibit adaptive resistance and benefit from MET inhibitor combination therapy. The gene discussed is BRAF; the disease is melanoma.